Angel Vinuela, MD
Internal Medicine · Dorado, PRNPI 1508192881
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $135,957 of the $181,633 with a category attached, or 74.9%. 15 manufacturers reported payments, led by AbbVie at 24.9% of the total. Among internal medicine clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 686 payments — averaging $264.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$45K
- Teva Pharmaceuticals USA, Inc.$44K
- Acadia Pharmaceuticals Inc$24K
- Amneal Pharmaceuticals LLC$23K
- Acorda Therapeutics, Inc$18K
- Medtronic$10K
- plus $18K from 9 others
What the payments were for
- Consulting fees$21,41712%
- Speaking & faculty fees$135,95775%
- Travel & lodging$11,2236%
- Food & beverage$12,0167%
- Education$1,0201%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 102 | $45,237 |
| Teva Pharmaceuticals USA, Inc. | 75 | $43,698 |
| Acadia Pharmaceuticals Inc | 136 | $24,270 |
| Amneal Pharmaceuticals LLC | 61 | $22,978 |
| Acorda Therapeutics, Inc | 27 | $18,143 |
| Medtronic(2 entities) | 191 | $9,711 |
| MDD US Operations, LLC | 19 | $6,256 |
| Kyowa Kirin, Inc. | 8 | $5,433 |
| Adamas Pharmaceuticals, Inc. | 25 | $3,762 |
| Abbott | 13 | $1,616 |
| Sunovion Pharmaceuticals Inc. | 19 | $319 |
| PBG Puerto Rico LLC | 5 | $110 |
| Supernus Pharmaceuticals, Inc. | 3 | $65 |
| Novartis | 1 | $20 |
| Eli Lilly Export S.A. Puerto Rico Branch | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$181,633 in reported general payments places this provider in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 807 | $4,099,439 |
| RytaryCarbidopa/Levodopa | 2,810 | $1,650,087 |
| GocovriAmantadine Hcl | 376 | $955,466 |
| AustedoDeutetrabenazine | 144 | $819,118 |
| ApokynApomorphine Hcl | 27 | $762,055 |
| Austedo XrDeutetrabenazine | 38 | $325,223 |
| NeuproRotigotine | 231 | $205,306 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 3,072 | $194,642 |
| InbrijaLevodopa | 41 | $147,224 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 4,755 | $128,147 |
| MyrbetriqMirabegron | 97 | $52,423 |
| BotoxOnabotulinumtoxina | 41 | $46,704 |
| RivastigmineRivastigmine Tartrate | 835 | $37,180 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 258 | $36,171 |
| AmantadineAmantadine Hcl | 918 | $29,195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $24,270 | $4,099,439807 claims |
| Amneal Pharmaceuticals LLCRytary | $22,978 | $1,650,0872,810 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $43,698 | $1,144,341182 claims |
| MDD US Operations, LLCGocovri | $6,256 | $955,466376 claims |
| Acorda Therapeutics, IncInbrija | $18,143 | $147,22441 claims |
| AbbVieBotox, Linzess | $45,237 | $68,25780 claims |
| Kyowa Kirin, Inc.Nourianz | $5,433 | $24,06713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Other internal medicine in Dorado
- Ivanisse Ortiz VelezDorado$5K
- Nelson VallejoLas Piedras$621K
- Ricardo FernandezSan Juan$351K
- Ronald Collazo PaganManati$206K
- Julio JimenezSan Lorenzo$99K
- Luis Negron GarciaSan German$24K
- Jorge Torres OlmedaCoto Laurel$23K
- Norma SalgadoSan Juan$21K
- Victor Gordo GonzalezSan Juan$21K
- Luis Rivera ColonRio Piedras$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.